Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor <i>KRAS</i> and <i>BRAF</i> Mutation Status

Van Cutsem, Eric; Köhne, Claus-Henning; Láng, István; Folprecht, Gunnar; P. Nowacki, Marek; Cascinu, Stefano; Shchepotin, I.; Maurel, Joan; Cunningham, David; Tejpar, Sabine; Schlichting, Michael; Zubel, Angela; Celik, Ilhan; Rougier, Philippe; Ciardiello, Fortunato

doi:10.1200/jco.2010.33.5091

Public

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

Published in Journal of Clinical Oncology • Apr 19, 2011

Authors:

Eric Van Cutsem

Claus-Henning Köhne

István Láng

Abstract

PURPOSE: The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated surviva...

Subject

Cetuximab

FOLFIRI

KRAS

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!